Molecular clonality determination of ipsilateral recurrence of invasive breast carcinomas after breast-conserving therapy: Comparison with clinical and biologic factors

American Journal of Clinical Pathology

Volumn 123, Issue 5, 2005, Pages 679-689

  Goldstein, Neal S ^a   Vicini, Frank A ^a   Hunter, Susan ^a   Odish, Eva ^a   Forbes, Suzy ^a   Kraus, Daniel ^a   Kestin, Larry L ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

Breast; Clonality; Local failure; Loss of heterozygosity; Metastases; Molecular; Pathology

Indexed keywords

ALLELIC EXCLUSION; ARTICLE; BREAST CARCINOMA; CANCER INVASION; CANCER LOCALIZATION; CANCER RECURRENCE; CLINICAL ARTICLE; CLONAL VARIATION; CONTROLLED STUDY; FEMALE; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; HUMAN TISSUE; METASTASIS POTENTIAL; MOLECULAR BIOLOGY; MOLECULAR CLONALITY; PARTIAL MASTECTOMY; PATIENT SELECTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECURRENCE RISK; RECURRENT CANCER; SECOND CANCER;

EID: 17844377869     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/DP47PK9PVC52AU4R     Document Type: Article

References (90)

1. Lasko D, Cavenee W, Nordenskjold M. Loss of constitutional heterozygosity in human cancer. Annu Rev Genet. 1991;25:281-314.
2. Sidransky D. Nucleic acid-based methods for the detection of cancer. Science. 1997;278:1054-1059.
3. Bianchi AB, Navone NM, Conti CJ. Detection of loss of heterozygosity in formalin-fixed paraffin-embedded tumor specimens by the polymerase chain reaction. Am J Pathol. 1991;138:279-284.
4. Wang Y, Hung SC, Linn JF, et al. Microsatellite-based cancer detection using capillary array electrophoresis and energy-transfer fluorescent primers. Electrophoresis. 1997;18:1742-1749.
5. Sell SM, Patel S, Stracner D, et al. Allelic loss analysis by capillary electrophoresis: an accurate, automated method for detection of deletions in solid tumors. Genet Test. 2001;5:267-268.
6. Medintz IL, Lee CC, Wong WW, et al. Loss of heterozygosity assay for molecular detection of cancer using energy-transfer primers and capillary array electrophoresis. Genome Res. 2000;10:1211-1218.
7. Mead LJ, Gillespie MT, Hung JY, et al. Frequent loss of heterozygosity in early non-small cell lung cancers at chromosome 9p21 proximal to the CDKN2a gene. Int J Cancer. 1997;71:213-217.
8. Anami Y, Matsuno Y, Yamada T, et al. A case of double primary adenocarcinoma of the lung with multiple atypical adenomatous hyperplasia. Pathol Int. 1998;48:634-640.
9. Leong PP, Rezai B, Koch WM, et al. Distinguishing second primary tumors from lung metastases in patients with head and neck squamous cell carcinoma. J Natl Cancer Inst. 1998;90:972-977.
10. Kollias J, Man S, Marafie M, et al. Loss of heterozygosity in bilateral breast cancer. Breast Cancer Res Treat. 2000;64:241-251.
11. Kung FY, Tse GM, Lo KW, et al. Metachronous bilateral mammary metaplastic and infiltrating duct carcinomas: a molecular study for clonality. Hum Pathol. 2002;33:677-679.
12. Lininger RA, Fujii H, Man YG, et al. Comparison of loss heterozygosity in primary and recurrent ductal carcinoma in situ of the breast. Mod Pathol. 1998;11:1151-1159.
13. Regitnig P, Moser R, Thalhammer M, et al. Microsatellite analysis of breast carcinoma and corresponding local recurrences. J Pathol. 2002;198:190-197.
14. Regitnig P, Ploner F, Maderbacher M, et al. Bilateral carcinomas of the breast with local recurrence: analysis of genetic relationship of the tumors. Mod Pathol. 2004;17:597-602.
15. Tse GM, Kung FY, Chan AB, et al. Clonal analysis of bilateral mammary carcinomas by clinical evaluation and partial allelotyping. Am J Clin Pathol. 2003;120:168-174.
16. Schlechter BL, Yang Q, Larson PS, et al. Quantitative DNA fingerprinting may distinguish new primary breast cancer from disease recurrence. J Clin Oncol 2004;22:1830-1838.
17. Hampl M, Hampl JA, Reiss G, et al. Loss of heterozygosity accumulation in primary breast carcinomas and additionally in corresponding distant metastases is associated with poor outcome. Clin Cancer Res. 1999;5:1417-1425.
18. Goldstein NS, Kestin L, Vicini F. Factors associated with ipsilateral breast failure and distant metastases in patients with invasive breast carcinoma treated with breast-conserving therapy: a clinicopathologic study of 607 neoplasms from 583 patients. Am J Clin Pathol. 2003;120:500-527.
19. Elkhuizen PH, van de Vijver MJ, Hermans J, et al. Local recurrence after breast-conserving therapy for invasive breast cancer: high incidence in young patients and association with poor survival. Int J Radiat Oncol Biol Phys. 1998;40:859-867.
20. Elkhuizen PH, Hermans J, Leer JW, et al. Isolated late local recurrences with high mitotic count and early local recurrences following breast-conserving therapy are associated with increased risk on distant metastasis. Int J Radiat Oncol Biol Phys. 2001;50:387-396.
21. Fisher ER, Anderson S, Tan-Chiu E, et al. Fifteen-year prognostic discriminants for invasive breast carcinoma: National Surgical Adjuvant Breast and Bowel Project Protocol-06. Cancer. 2001;91:1679-1687.
22. Fortin A, Larochelle M, Laverdiere J, et al. Local failure is responsible for the decrease in survival for patients with breast cancer treated with conservative surgery and postoperative radiotherapy. J Clin Oncol. 1999;17:101-109.
23. Fowble B. Ipsilateral breast tumor recurrence following breast-conserving surgery for early-stage invasive cancer. Acta Oncol. 1999;38(suppl 13):9-17.
24. Haffty BG, Reiss M, Beinfield M, et al. Ipsilateral breast tumor recurrence as a predictor of distant disease: implications for systemic therapy at the time of local relapse. J Clin Oncol. 1996;14:52-57.
25. Veronesi U, Marubini E, del Vecchio M, et al. Local recurrences and distant metastases after conservative breast cancer treatments: partly independent events. J Natl Cancer Inst. 1995;87:19-27.
26. Whelan T, Clark R, Roberts R, et al, for the Investigators of the Ontario Clinical Oncology Group. Ipsilateral breast tumor recurrence postlumpectomy is predictive of subsequent mortality: results from a randomized trial. Int J Radiat Oncol Biol Phys. 1994;30:11-16.
27. Huang E, Buchholz TA, Meric F, et al. Classifying local disease recurrences after breast conservation therapy based on location and histology: new primary tumors have more favorable outcomes than true local disease recurrences. Cancer. 2002;95:2059-2067.
28. Vicini FA, Kestin L, Huang R, et al. Does local recurrence affect the rate of distant metastases and survival in patients with early-stage breast carcinoma treated with breast-conserving therapy? Cancer. 2003;97:910-919.
29. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer, I: the value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19:403-410.
30. Recht A, Silver B, Schnitt S, et al. Breast relapse following primary radiation therapy for early breast cancer, I: classification, frequency and salvage. Int J Radiat Oncol Biol Phys. 1985;11:1271-1276.
31. Sieben NL, ter Haar NT, Cornelisse CJ, et al. PCR artifacts in LOH and MSI analysis of microdissected tumor cells. Hum Pathol. 2000;31:1414-1419.
32. Going JJ. Stages on the way to breast cancer. J Pathol. 2003;199:1-3.
33. Fujii H, Anbazhagan R, Bomman DM, et al. Mucinous cancers have fewer genomic alterations than more common classes of breast cancer. Breast Cancer Res Treat. 2002;76:255-260.
34. Aubele M, Werner M, Hofler H. Genetic alterations in presumptive precursor lesions of breast carcinomas. Anal Cell Pathol. 2002;24:69-76.
35. Kaneko M, Arihiro K, Takeshima Y, et al. Loss of heterozygosity and microsatellite instability in epithelial hyperplasia of the breast. J Exp Ther Oncol. 2002;2:9-18.
36. Bijker N, Peterse JL, Duchateau L, et al. Histological type and marker expression of the primary tumour compared with its local recurrence after breast-conserving therapy for ductal carcinoma in situ. Br J Cancer. 2001;84:539-544.
37. Ando Y, Iwase H, Ichihara S, et al. Loss of heterozygosity and microsatellite instability in ductal carcinoma in situ of the breast. Cancer Lett. 2000;156:207-214.
38. Chappell SA, Walsh T, Walker RA, et al. Loss of heterozygosity at chromosome 6q in preinvasive and early invasive breast carcinomas. Br J Cancer. 1997;75:1324-1329.
39. Champeme MH, Bieche I, Lizard S, et al. 11q13 amplification in local recurrence of human primary breast cancer. Genes Chromosomes Cancer. 1995;12:128-133.
40. Vrieling C, Collette L, Fourquet A, et al. Can patient-, treatment- and pathology-related characteristics explain the high local recurrence rate following breast-conserving therapy in young patients? Eur J Cancer. 2003;39:932-944.
41. Koukourakis MI, Giatromanolaki A, Galazios G, et al. Molecular analysis of local relapse in high-risk breast cancer patients: can radiotherapy fractionation and time factors make a difference? Br J Cancer. 2003;88:711-717.
42. Dalberg K, Liedberg A, Johansson U, et al. Uncontrolled local disease after salvage treatment for ipsilateral breast tumour recurrence. Eur J Surg Oncol. 2003;29:143-154.
43. Luqmani YA, Mathew M, Lobo S. Frequent microsatellite alterations in a predominantly younger age of onset breast cancer population. Int J Mol Med. 2003;11:117-124.
44. Komoike Y, Motomura K, Inaji H, et al. Repeat lumpectomy for patients with ipsilateral breast tumor recurrence after breast-conserving surgery: preliminary results. Oncology. 2003;64:1-6.
45. Tsuneizumi M, Emi M, Hirano A, et al. Association of allelic loss at 8p22 with poor prognosis among breast cancer cases treated with high-dose adjuvant chemotherapy. Cancer Lett. 2002;180:75-82.
46. Euhus DM, Cler L, Shivapurkar N, et al. Loss of heterozygosity in benign breast epithelium in relation to breast cancer risk. J Natl Cancer Inst. 2002;94:858-860.
47. Roncuzzi L, Brognara I, Cocchi S, et al. Loss of heterozygosity at pseudoautosomal regions in human breast cancer and association with negative hormonal phenotype. Cancer Genet Cytogenet. 2002;135:173-176.
48. Zudaire I, Odero MD, Caballero C, et al. Genomic imbalances detected by comparative genomic hybridization are prognostic markers in invasive ductal breast carcinomas. Histopathology. 2002;40:547-555.
49. Johnson SM, Shaw JA, Walker RA. Sporadic breast cancer in young women: prevalence of loss of heterozygosity at p53, BRCA1 and BRCA2. Int J Cancer. 2002;98:205-209.
50. Farabegoli F, Champeme MH, Bieche I, et al. Genetic pathways in the evolution of breast ductal carcinoma in situ. J Pathol. 2002;196:280-286.
51. Selim AG, Ryan A, El Ayat G, et al. Loss of heterozygosity and allelic imbalance in apocrine metaplasia of the breast: microdissection microsatellite analysis. J Pathol. 2002;196:287-291.
52. Li Z, Moore DH, Meng ZH, et al. Increased risk of local recurrence is associated with allelic loss in normal lobules of breast cancer patients. Cancer Res. 2002;62:1000-1003.
53. Nagahata T, Hirano A, Utada Y, et al. Correlation of allelic losses and clinicopathological factors in 504 primary breast cancers. Breast Cancer. 2002;9:208-215.
54. Roylance R, Gorman P, Hanby A, et al. Allelic imbalance analysis of chromosome 16q shows that grade I and grade III invasive ductal breast cancers follow different genetic pathways. J Pathol 2002;196:32-36.
55. Ozer E, Yuksel E, Kizildag S, et al. Microsatellite instability in early-onset breast cancer. Pathol Res Pract. 2002;198:525-530.
56. Taback B, Giuliano AE, Hansen NM, et al. Microsatellite alterations detected in the serum of early stage breast cancer patients. Ann N Y Acad Sci. 2001;945:22-30.
57. Forsti A, Louhelainen J, Soderberg M, et al. Loss of heterozygosity in tumour-adjacent normal tissue of breast and bladder cancer. Eur J Cancer. 2001;37:1372-1380.
58. Ottini L, Palli D, Falchetti M, et al. Instability at dinucleotide and trinucleotide repeats in breast cancer. Int J Oncol. 2000;17:819-826.
59. Wild P, Knuechel R, Dietmaier W, et al. Laser microdissection and microsatellite analyses of breast cancer reveal a high degree of tumor heterogeneity. Pathobiology. 2000;68:180-190.
60. Brekelmans CT, Voogd AC, Botke G, et al, for the Dutch Study Group on Local Recurrence after Breast Conservation (BORST). Family history of breast cancer and local recurrence after breast-conserving therapy. Eur J Cancer. 1999;35:620-626.
61. Sieben NL, Kolkman-Uljee SM, Flanagan AM, et al. Molecular genetic evidence for monoclonal origin of bilateral ovarian serous borderline tumors. Am J Pathol. 2003;162:1095-1101.
62. Amari M, Moriya T, Ishida T, et al. Loss of heterozygosity analyses of asynchronous lesions of ductal carcinoma in situ and invasive ductal carcinoma of the human breast. Jpn J Clin Oncol. 2003;33:556-562.
63. Kurtz JM, Spitalier JM, Amalric R, et al. The prognostic significance of late local recurrence after breast-conserving therapy. Int J Radiat Oncol Biol Phys. 1990;18:87-93.
64. Kurtz JM, Amalric R, Brandone H, et al. Local recurrence after breast-conserving surgery and radiotherapy: frequency, time course, and prognosis. Cancer. 1989;63:1912-1917.
65. Haffty BG, Fischer D, Rose M, et al. Prognostic factors for local recurrence in the conservatively treated breast cancer patient: a cautious interpretation of the data. J Clin Oncol. 1991;9:997-1003.
66. Haffty BG, Carter D, Flynn SD, et al. Local recurrence versus new primary: clinical analysis of 82 breast relapses and potential applications for genetic fingerprinting. Int J Radiat Oncol Biol Phys. 1993;27:575-583.
67. Fredriksson I, Liljegren G, Arnesson LG, et al. Local recurrence in the breast after conservative surgery: a study of prognosis and prognostic factors in 391 women. Eur J Cancer. 2002;38:1860-1870.
68. Doyle T, Schultz DJ, Peters C, et al. Long-term results of local recurrence after breast conservation treatment for invasive breast cancer. Int J Radiat Oncol Biol Phys. 2001;51:74-80.
69. Meijer-van Gelder ME, Look MP, Bolt-De VJ, et al. Breast-conserving therapy: proteases as risk factors in relation to survival after local relapse. J Clin Oncol. 1999;17:1449-1457.
70. Fisher B, Anderson S, Fisher ER, et al. Significance of ipsilateral breast tumour recurrence after lumpectomy. Lancet. 1991;338:327-331.
71. Fourquet A, Campana F, Zafrani B, et al. Prognostic factors of breast recurrence in the conservative management of early breast cancer: a 25-year follow-up. Int J Radiat Oncol Biol Phys. 1989;17:719-725.
72. Moran MS, Haffty BG. Local-regional breast cancer recurrence: prognostic groups based on patterns of failure. Breast J. 2002;8:81-87.
73. Le MG, Arriagada R, Spielmann M, et al. Prognostic factors for death after an isolated local recurrence in patients with early-stage breast carcinoma. Cancer. 2002;94:2813-2820.
74. McBain CA, Young EA, Swindell R, et al. Local recurrence of breast cancer following surgery and radiotherapy: incidence and outcome. Clin Oncol (R Coll Radiol). 2003;15:25-31.
75. Meric F, Mirza NQ, Vlastos G, et al. Positive surgical margins and ipsilateral breast tumor recurrence predict disease-specific survival after breast-conserving therapy. Cancer. 2003;97:926-933.
76. Lakhani SR, Slack DN, Hamoudi RA, et al. Detection of allelic imbalance indicates that a proportion of mammary hyperplasia of usual type are clonal, neoplastic proliferations. Lab Invest. 1996;74:129-135.
77. O'Connell P, Pekkel V, Fuqua SA, et al. Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. J Natl Cancer Inst. 1998;90:697-703.
78. Lakhani SR, Chaggar R, Davies S, et al. Genetic alterations in "normal" luminal and myoepithelial cells of the breast. J Pathol 1999;189:496-503.
79. Zucca MP, Larson PS, Rosenberg CL, et al. Lack of correlation between morphometric analysis and presence of microsatellite alterations in proliferative ductal lesions of the breast. Anal Quant Cytol Histol. 1999;21:369-373.
80. Marinho AF, Botelho M, Schmitt FC. Evaluation of numerical abnormalities of chromosomes 1 and 17 in proliferative epithelial breast lesions using fluorescence in situ hybridization. Pathol Res Pract. 2000;196:227-233.
81. Moinfar F, Man YG, Bratthauer GL, et al. Genetic abnormalities in mammary ductal intraepithelial neoplasia-flat type ("clinging ductal carcinoma in situ"): a simulator of normal mammary epithelium. Cancer. 2000;88:2072-2081.
82. Larson PS, de las Morenas A, Cupples LA, et al. Genetically abnormal clones in histologically normal breast tissue. Am J Pathol. 1998;152:1591-1598.
83. Lichy JH, Dalbegue F, Zavar M, et al. Genetic heterogeneity in ductal carcinoma of the breast. Lab Invest. 2000;80:291-301.
84. Gong G, DeVries S, Chew KL, et al. Genetic changes in paired atypical and usual ductal hyperplasia of the breast by comparative genomic hybridization. Clin Cancer Res. 2001;7:2410-2414.
85. Jones C, Merrett S, Thomas VA, et al. Comparative genomic hybridization analysis of bilateral hyperplasia of usual type of the breast. J Pathol. 2003;199:152-156.
86. Larson PS, de las Morenas A, Bennett SR, et al. Loss of heterozygosity or allele imbalance in histologically normal breast epithelium is distinct from loss of heterozygosity or allele imbalance in co-existing carcinomas. Am J Pathol. 2002;161:283-290.
87. Tsuda H, Takarabe T, Akashi-Tanaka S, et al. Pattern of chromosome 16q loss differs between an atypical proliferative lesion and an intraductal or invasive ductal carcinoma occurring subsequently in the same area of the breast. Mod Pathol. 2001;14:382-388.
88. Boecker W, Buerger H, Schmitz K, et al. Ductal epithelial proliferations of the breast: a biological continuum? comparative genomic hybridization and high-molecular-weight cytokeratin expression patterns. J Pathol. 2001;195:415-421.
89. Buerger H, Otterbach F, Simon R, et al. Different genetic pathways in the evolution of invasive breast cancer are associated with distinct morphological subtypes. J Pathol. 1999;189:521-526.
90. Buerger H, Otterbach F, Simon R, et al. Comparative genomic hybridization of ductal carcinoma in situ of the breast: evidence of multiple genetic pathways. J Pathol. 1999;187:396-402.